Therapix Licenses Yissum’s Technology for Nasal Drug Delivery of Cannabinoids


Therapix Yissum
Therapix Signs Exclusive License Agreement with Yissum for Nasal Drug Delivery Technology

Agreement Paves the Way for Development and Marketing of New Cannabinoid-based Treatment Offerings for Mild Cognitive Impairment and other Neurological Conditions

TEL-AVIV, Israel, April 5, 2017 /PRNewswire/ —

Therapix Biosciences Ltd. (NASDAQ, TASE: TRPX), a specialty

... read more at: https://www.newcannabisventures.com/therapix-licenses-yissums-technology-for-nasal-drug-delivery-of-cannabinoids/